Payment overview · 2025
General Payments
$2,393.87
132 reported records · 23 companies
Healthcare provider profile · identity verified
Lawrence I. Lee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ALABASTER, AL · NPI 1063424935
Verified facts
What the public records show
CMS Open Payments records show Lawrence I. Lee, M.D. received $2,393.87 in general payments during 2025 across 132 reported records.
ABBVIE INC. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 673 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $332.38 | 13.9% | 24 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $300.94 | 12.6% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $256.59 | 10.7% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $200.58 | 8.4% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $166.28 | 7.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $165.88 | 6.9% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $135.43 | 5.7% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $103.53 | 4.3% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.60 | 4.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $91.36 | 3.8% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $87.87 | 3.7% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.66 | 2.8% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $63.26 | 2.6% | 4 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $56.44 | 2.4% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $42.14 | 1.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.94 | 1.8% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.20 | 1.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.92 | 1.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.60 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.0% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $22.95 | 1.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.66 | 0.9% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $20.66 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,382.31 | 131 |
| Education | $11.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $300.94 | 15 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $288.08 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $279.56 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $198.60 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $183.60 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $166.28 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $148.08 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $135.43 | 11 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $133.78 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $114.53 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.31 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.60 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $91.36 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $90.99 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $69.21 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.08 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $63.26 | 4 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $42.14 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.94 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.20 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.32 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $22.95 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 673 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
129 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
169 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
673 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 32 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1348 | 255 |
| Amlodipine Besylate | Amlodipine Besylate | 1305 | 262 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1137 | 234 |
| Pantoprazole Sodium | Pantoprazole Sodium | 877 | 203 |
| Gabapentin | Gabapentin | 754 | 148 |
| Potassium Chloride | Potassium Chloride | 679 | 138 |
| Eliquis | Apixaban | 673 | 85 |
| Losartan Potassium | Losartan Potassium | 619 | 136 |
| Lisinopril | Lisinopril | 595 | 128 |
| Metformin Hcl | Metformin Hcl | 546 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 542 | 129 |
| Trazodone Hcl | Trazodone Hcl | 514 | 112 |
| Carvedilol | Carvedilol | 509 | 108 |
| Omeprazole | Omeprazole | 476 | 117 |
| Furosemide | Furosemide | 474 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 453 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 430 | 86 |
| Sertraline Hcl | Sertraline Hcl | 420 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 413 | 82 |
| Mirtazapine | Mirtazapine | 389 | 87 |
| Donepezil Hcl | Donepezil Hcl | 385 | 65 |
| Memantine Hcl | Memantine Hcl | 385 | 71 |
| Levetiracetam | Levetiracetam | 379 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 367 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 356 | 69 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 355 | 109 |
| Meloxicam | Meloxicam | 302 | 76 |
| Hydralazine Hcl | Hydralazine Hcl | 298 | 58 |
| Simvastatin | Simvastatin | 284 | 63 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 282 | 51 |
| Quetiapine Fumarate | Quetiapine Fumarate | 282 | 51 |
| Clonazepam | Clonazepam | 266 | 41 |
| Tramadol Hcl | Tramadol Hcl | 266 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 262 | 57 |
| Clopidogrel | Clopidogrel Bisulfate | 260 | 52 |
| Divalproex Sodium | Divalproex Sodium | 259 | 48 |
| Prednisone | Prednisone | 256 | 173 |
| Famotidine | Famotidine | 254 | 54 |
| Glimepiride | Glimepiride | 248 | 58 |
| Olanzapine | Olanzapine | 247 | 42 |
| Diclofenac Sodium | Diclofenac Sodium | 231 | 67 |
| Montelukast Sodium | Montelukast Sodium | 231 | 57 |
| Humalog Kwikpen U-100 | Insulin Lispro | 228 | 47 |
| Valsartan | Valsartan | 223 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 218 | 46 |
| Sucralfate | Sucralfate | 204 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 197 | 49 |
| Xarelto | Rivaroxaban | 196 | 23 |
| Lorazepam | Lorazepam | 195 | 48 |
| Buspirone Hcl | Buspirone Hcl | 188 | 35 |
| Alprazolam | Alprazolam | 185 | 31 |
| Baclofen | Baclofen | 184 | 25 |
| Topiramate | Topiramate | 184 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 172 | 116 |
| Trulicity | Dulaglutide | 169 | 21 |
| Allopurinol | Allopurinol | 168 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 160 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 144 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 138 | 25 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 134 | 110 |
| Linzess | Linaclotide | 129 | 11 |
| Atenolol | Atenolol | 126 | 25 |
| Lovastatin | Lovastatin | 122 | 33 |
| Fenofibrate | Fenofibrate | 119 | 28 |
| Methocarbamol | Methocarbamol | 118 | 32 |
| Lactulose | Lactulose | 117 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 109 | 84 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 30 |
| Bupropion Xl | Bupropion Hcl | 105 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 103 | 27 |
| Farxiga | Dapagliflozin Propanediol | 101 | 15 |
| Latanoprost | Latanoprost | 101 | 15 |
| Ibuprofen | Ibuprofen | 98 | 21 |
| Lacosamide | Lacosamide | 98 | 15 |
| Myrbetriq | Mirabegron | 95 | 11 |
| Risperidone | Risperidone | 94 | 13 |
| Azithromycin | Azithromycin | 93 | 75 |
| Aripiprazole | Aripiprazole | 92 | 13 |
| Pregabalin | Pregabalin | 92 | 21 |
| Ezetimibe | Ezetimibe | 91 | 23 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 91 | 32 |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 90 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 89 | 41 |
| Metformin Hcl Er | Metformin Hcl | 87 | 22 |
| Oxcarbazepine | Oxcarbazepine | 85 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 84 | 18 |
| Memantine Hcl Er | Memantine Hcl | 84 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 83 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 83 | 15 |
| Rexulti | Brexpiprazole | 81 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 15 |
| Novolog Flexpen | Insulin Aspart | 80 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 79 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 79 | 14 |
| Clonidine Hcl | Clonidine Hcl | 77 | 30 |
| Primidone | Primidone | 77 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 21 |
| Midodrine Hcl | Midodrine Hcl | 75 | 18 |
| Jardiance | Empagliflozin | 73 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 72 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 18 |
| Ozempic | Semaglutide | 72 | 11 |
| Ceftriaxone | Ceftriaxone Sodium | 71 | 60 |
| Alendronate Sodium | Alendronate Sodium | 70 | 12 |
| Spironolactone | Spironolactone | 70 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 69 | 14 |
| Haloperidol | Haloperidol | 68 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 19 |
| Nystatin | Nystatin | 67 | 33 |
| Diazepam | Diazepam | 66 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 66 | 52 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 23 |
| Fluconazole | Fluconazole | 63 | 44 |
| Celecoxib | Celecoxib | 62 | 19 |
| Glipizide | Glipizide | 61 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 57 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 16 |
| Ramipril | Ramipril | 56 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 12 |
| Digoxin | Digoxin | 54 | suppressed |
| Levofloxacin | Levofloxacin | 53 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 38 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 39 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | suppressed |
| Paliperidone Er | Paliperidone | 48 | suppressed |
| Budesonide | Budesonide | 47 | 11 |
| Finasteride | Finasteride | 47 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 47 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 47 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 36 |
| Sodium Chloride | 0.9 % Sodium Chloride | 45 | 22 |
| Xifaxan | Rifaximin | 45 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 44 | suppressed |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Permethrin | Permethrin | 44 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 41 | suppressed |
| Glipizide Er | Glipizide | 41 | suppressed |
| Testosterone | Testosterone | 41 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Mounjaro | Tirzepatide | 36 | 11 |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 30 |
| Ingrezza | Valbenazine Tosylate | 35 | suppressed |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 18 |
| Amoxicillin | Amoxicillin | 33 | 22 |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Cephalexin | Cephalexin | 33 | 29 |
| Estradiol | Estradiol | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 32 |
| Risedronate Sodium | Risedronate Sodium | 33 | 11 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Oxycontin | Oxycodone Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Letrozole | Letrozole | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | 11 |
| Belsomra | Suvorexant | 27 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 13 |
| Meclizine Hcl | Meclizine Hcl | 26 | 11 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 18 |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Amantadine | Amantadine Hcl | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 15 |
| Sulfasalazine | Sulfasalazine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 22 | suppressed |
| Valproic Acid | Valproic Acid | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Triazolam | Triazolam | 20 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Zonisamide | Zonisamide | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 15 |
| Cyclosporine | Cyclosporine | 17 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 17 | suppressed |
| Galantamine Er | Galantamine Hbr | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Ivermectin | Ivermectin | 17 | 15 |
| Lidocaine | Lidocaine | 17 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Acetylcysteine | Acetylcysteine | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 13 | 12 |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 12 |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,393.87 · 132 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AREXVY, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Dyanavel XR, ELIQUIS, FARXIGA, IBSRELA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, RECORLEV, RELISTOR, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XHANCE, XIFAXAN, XYOSTED, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error